Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 11/20 | 1.00 |
| ▸ | DGAT2 | Q96PD7 | 4/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16854405 | 0.88 | ADRA1A (1.00) | ADRA1AL3MBTL3L3MBTL1POLB | |
| SCHEMBL16827278 | 0.81 | ADRA1A (1.00) | ADRA1ADGAT2L3MBTL3L3MBTL1 | |
| SCHEMBL31482152 | 0.75 | ADRA1A (0.60) | ADRA1AL3MBTL3L3MBTL1ADRA2C | |
| SCHEMBL16845133 | 0.75 | ADRA1A (0.62) | ADRA1AL3MBTL3L3MBTL1 | |
| SCHEMBL16845100 | 0.73 | ADRA1A (0.60) | ADRA1AL3MBTL3L3MBTL1 | |
| SCHEMBL18199524 | 0.73 | ADRA1A (0.59) | ADRA1AL3MBTL3L3MBTL1 | |
| SCHEMBL28842787 | 0.73 | ADRA1A (0.55) | ADRA1AL3MBTL3L3MBTL1ADRA2C | |
| Hydrochloric Acid SCHEMBL18185613 | 0.72 | ADRA1A (0.59) | ADRA1AL3MBTL3L3MBTL1 | |
| SCHEMBL31482196 | 0.72 | ADRA1A (0.57) | ADRA1AL3MBTL3L3MBTL1ADRA2C | |
| SCHEMBL18185578 | 0.72 | ADRA1A (0.58) | ADRA1AL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624199-B2 | Substituted bipiperidinyl derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624199-B2 | Substituted bipiperidinyl derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-9624199-B2 | Substituted bipiperidinyl derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20160304492-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-20 | — | — | US | disclosed |
| WO-2015091420-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES AS ADRENORECEPTOR ALPHA 2C ANTAGONISTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304492-A1 | SUBSTITUTED BIPIPERIDINYL DERIVATIVES | TNNC1, TNNI3, FABP3 | ADRA1A 1176/4885DGAT2 4042/4885L3MBTL3 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.